(Q37765198)

22 August 2017

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel (English)

1 reference

22 August 2017

metastatic breast cancer

1 reference

11

Jacek Jassem

1 reference

22 August 2017

9

Renata Duchnowska

1 reference

22 August 2017

19

Valentina Tzekova

1 reference

22 August 2017

6

Alvydas Cesas

1 reference

22 August 2017

17

Gunta Purkalne

1 reference

22 August 2017

18

Constanta Timcheva

1 reference

22 August 2017

3

Florin Bacanu

1 reference

22 August 2017

10

Alexandru Eniu

1 reference

22 August 2017

Guenther G Steger

1

1 reference

22 August 2017

Jitka Abrahámová

2

1 reference

22 August 2017

Stephen Brincat

4

1 reference

22 August 2017

Arija Brize

5

1 reference

22 August 2017

Tanja Cufer

7

1 reference

22 August 2017

Magdolna Dank

8

1 reference

22 August 2017

Zsuzsanna Kahán

12

1 reference

22 August 2017

Erika Matos

13

1 reference

22 August 2017

Peeter Padrik

14

1 reference

22 August 2017

Signe Plāte

15

1 reference

22 August 2017

Helis Pokker

16

1 reference

22 August 2017

Rostislav Vyzula

20

1 reference

22 August 2017

Christoph C Zielinski

21

1 reference

22 August 2017

15 June 2010

1 reference

22 August 2017

Vienna Clinical Weekly

1 reference

22 August 2017

122

1 reference

22 August 2017

11-12

1 reference

22 August 2017

368-379

1 reference

https://scigraph.springernature.com/pub.10.1007/s00508-010-1373-6

22 August 2017

0 references

cites work

Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00508-010-1373-6

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review

1 reference

12 December 2020

Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

1 reference

12 December 2020

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

1 reference

12 December 2020

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

12 December 2020

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

12 December 2020

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

1 reference

12 December 2020

Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials

1 reference

12 December 2020

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

1 reference

12 December 2020

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer

1 reference

12 December 2020

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Her2 cross talk and therapeutic resistance in breast cancer

1 reference

12 December 2020

Facts and controversies in systemic treatment of metastatic breast cancer

1 reference

12 December 2020

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

12 December 2020

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

1 reference

12 December 2020

Regulation and targets of receptor tyrosine kinases

1 reference

12 December 2020

Is breast cancer survival improving?

1 reference

12 December 2020

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

12 December 2020

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

Her-2 targeted therapy: beyond breast cancer and trastuzumab

1 reference

12 December 2020

Taxanes in breast cancer: an update

1 reference

12 December 2020

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

12 December 2020

Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

1 reference

12 December 2020

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

12 December 2020

Cardiovascular toxicity with cancer chemotherapy.

1 reference

12 December 2020

CNS metastases in breast cancer

1 reference

12 December 2020

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

12 December 2020

Second consensus on medical treatment of metastatic breast cancer

1 reference

12 December 2020

Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management

1 reference

12 December 2020

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

12 December 2020

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

12 December 2020

Single agent versus combination chemotherapy for metastatic breast cancer

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

1 reference

12 December 2020

Breast cancer with synchronous metastases: trends in survival during a 14-year period

1 reference

12 December 2020

Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer

1 reference

12 December 2020

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

1 reference

12 December 2020

Trastuzumab-induced cardiomyopathy.

1 reference

12 December 2020

10.1007/S00508-010-1373-6

Identifiers

DOI

1 reference

22 August 2017

1 reference